viernes, 28 de febrero de 2014

Low-Dose Statins Good Option for Some Heart Patients: Study

A new analysis suggests that people at high risk for heart disease who can't take high-dose statin drugs to lower their cholesterol might benefit from a treatment combination that includes taking a low-dose statin.
Scientists at Johns Hopkins reviewed published research to compare the benefits and harms of a lower-intensity statin when combined with one of several other cholesterol-lowering treatments in adults at high risk for heart disease.
Study author Dr. Kimberly Gudzune said combining a low-dose statin with either a so-called bile acid sequestrant or Zetia (ezetimibe) -- both of which are medications that also work to lower cholesterol levels -- lowered "bad" (LDL) cholesterol. Taking a high-dose statin by itself also lowered LDL levels.
"At least in the short term, this strategy seems to be as effective as the high-dose statin alone, although there were two major caveats: We don't know much about side effects and we don't know about long-term effectiveness," said Gudzune, an assistant professor of medicine at Johns Hopkins.
She also said the researchers were not able to draw conclusions about mortality or heart problems such as heart attacks.
There was not enough evidence regarding LDL cholesterol reduction when it came to using a low-dose statin with fibrates, niacin or omega-3 fatty acids, Gudzune said. Fibrates can lower levels of blood fats known as triglycerides and can sometimes raise levels of "good" (HDL) cholesterol.
The review was published online Feb. 10 in the journal Annals of Internal Medicine.
The American College of Cardiology and the American Heart Association cholesterol guidelines recommend moderate- or high-intensity statin therapy for people whose medical conditions or cholesterol levels put them at risk for heart disease -- the leading cause of death for both men and women in the United States.
But some patients don't respond to high doses of statins and some suffer from side effects, including muscle pain, Gudzune said.
"It doesn't happen infrequently that patients come in and say, 'I'm having muscle pains on this statin,'" she said. "So we wanted to review the literature and help shed a little bit of light on it for those patients."
Gudzune said they aren't yet sure of the long-term benefits of combining low-dose statins and other medications.
"Unfortunately, we weren't really able to examine the risk for [heart] events like heart attacks or strokes," she said. "We aren't sure if it translates into decreased [heart] risk."
Dr. Chip Lavie is medical director of cardiac rehabilitation and preventive cardiology at the John Ochsner Heart and Vascular Institute in New Orleans.
"This is a nice paper," Lavie said. "But I suspect that many clinicians ... already know that a lower-dose statin combined with a second lipid agent -- most know this best with ezetimibe -- produced at least similar but probably slightly better [results] ... compared with lower-dose statins alone."
Based on the most recent guidelines, Lavie said, doctors should try to get patients to tolerate the proven therapies before resorting to other less proven "but potentially very effective treatment approaches."
Tomado de: HealthDay News. SOURCES: Kimberly Gudzune, M.D., M.P.H., assistant professor, medicine, Johns Hopkins University School of Medicine, Baltimore; Carl Lavie, M.D., professor, medicine, and medical director, cardiac rehabilitation and preventive cardiology, John Ochsner Heart and Vascular Institute, New Orleans, and Ochsner Clinical School, University of Queensland School of Medicine, Brisbane, Australia; Feb. 10, 2014, Annals of Internal Medicine, online

4 comentarios:

  1. Uno de los puntos importantes a destacar es esta nueva opción de tratamiento en pacientes "intolerantes" a las estatinas. Personalmente considero que se debe encaminar la investigación a identificar todos los efectos pleiotrópicos potenciales del uso de este esquema de tratamiento a largo plazo, como por ejemplo la disminución de la carga viral en pacientes con infección por VIH. Con esos resultados, se abriría una nueva línea de investigación en la que se estudie la actividad biológica de éstas. Es importante conocer las vías de investigación que se están (o llevaron) a cabo, con el fin de discernir el conocimiento generado y tomar decisiones que nos orienten a indicar el tratamiento más efectivo para el paciente. Por lo pronto yo me quedo igual que al principio, el estudio no aporta información novedosa suficiente.

    ResponderEliminar
  2. Me parece haber revisado ya algo acerca de este tema en el libro de farmacolog´ia de Goodman & Gilman, en el que proponen esquemas parecidos al mencionado en este art´iculo; Incluso proponen el consumo de estatinas cada tercer d´ia mencionando que el beneficio es el mismo que con la terapia diaria, ayudando a reducir el gasto econ´omico, pero afectando el apego al tratamiento por parte del paciente, pues as´i puede olvidar m´as f´acilmente cu´ando es que le toca su medicamento.

    Por lo que ya mencion´e creo que la publicaci´on no proporciona informaci´on novedosa que te pueda hacer elegir un esquema de tratamiento por encima de otro, pero sirve para recordar que existen otras alternativas para estos pacientes y elegir el que m´as beneficio les pueda proporcionar.

    ResponderEliminar
  3. Es curioso que se hayan puesto a pensar en la posible respuesta de las estatinas a bajas dosis sobre los niveles de Colesterol en pacientes quienes no lo toleran, lo que reportan no me parece relevante pirque como dice aun no hay resUltados a largo plazo y no pudieron evaluar la tasa de atques al corazon, es decir si hubo una mejoria a bajas dosis wue con la dosis habitual. Aunque no reportan los resultados a largo plazo mencionan que a corto muestran muy buena respuesta, asi que seria bueno utilizarlo en quienes no toleran o pueden ingerir dosis altas.

    Samantha silva Armendariz

    ResponderEliminar
  4. andrea monserrat uribe torres15 de marzo de 2014, 18:24

    Es interesante la combinacion que plantean ya que los efectos adversos a las estatinas hacen que los pacientes dejen de tomar el medicamento o no cumplan su plan terapeutico, asi como me gustaria saber si con esas dosis bajas aparecen reacciones o si tienen el mismo efecto sobre las LDL o las HDL. Ya que esto impacta en la salud cardiovascular y el riesgo de IAM o EVC.

    ResponderEliminar